Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Launched by BEIJING TSINGHUA CHANG GUNG HOSPITAL · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of two types of chemotherapy treatments, called hyperthermic intraperitoneal chemotherapy (HIPEC), on a specific condition known as pseudomyxoma peritonei (PMP). The study aims to compare the effectiveness of two different chemotherapy regimens: one using only cisplatin and the other using both cisplatin and docetaxel. By using a special technique called Flura-seq, researchers hope to understand how these treatments affect the tumors at a molecular level. This information could help improve treatment options for patients with PMP in the future.

To participate in the trial, individuals must be between 18 and 75 years old and have a confirmed diagnosis of pseudomyxoma peritonei. They should be in good overall health, with normal liver and kidney function, and have a good chance of surviving for more than a year. Participants will receive the chemotherapy treatments and be monitored to see how well the drugs work. It's important for potential participants to discuss any medical history with their doctor, as certain conditions and allergies may disqualify them from joining the study. This trial is currently recruiting patients, so there may be an opportunity to contribute to important research that could lead to better treatment options for PMP.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-75 years old, regardless of gender and race;
• • Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment;
• • KPS score ≥ 60, with expected survival time more than 12 months;
• • The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function;
• • No history of allergy to biological products;
• • No serious bacterial or viral infection;
• • Non-pregnancy and lactation;
• • The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment.
• Exclusion Criteria:
• • Highly allergic or with a history of severe allergies, especially to biological products;
• • Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination;
• • Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation;
• • T-lymphocyte carcinoma/tumor;
• • Patients with systemic infection or severe local infection requiring anti-infection treatment;
• • Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs;
• • Coagulation disorders (e.g., hemophilia);
• • Infectious diseases (e.g. HIV, RPR, active TB, etc.);
• • Pregnant or lactating women, or women who have pregnancy plans within half a year;
• • Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation;
• • Patients with severe autoimmune diseases;
• • Any life-threatening disease, physical condition or organ system dysfunction that the researcher believes may damage the safety of subjects and expose the research results to unnecessary risks; Drug-dependent persons;
• • Patients and/or authorized family members who refuse or do not actively sign the informed consent;
• • Participants in other clinical studies within 3 months.